



Taxane containing chemotherapy is effective for women with operable early breast cancer

Clinical question How effective is taxane* containing chemotherapy for women with operable early breast cancer? Bottom line Compared to non-taxane containing chemotherapy, taxane containing chemotherapy improves overall survival and disease-free survival in pre- or postmenopausal women with early breast cancer (cancer that has not spread beyond the breast or nearby lymph nodes and is potentially curable by surgery alone). Caveat The review did not identify a subgroup of patients where taxane containing treatment may have been more or less effective. Dosage and scheduling of the taxanes used were not clearly defined so determining the optimal use of taxanes must await the next generation of studies. Context Breast cancer is the commonest cancer in women (23% of all cancers), with an estimated 1.15 million new cases and over 411,000 deaths reported worldwide in 2002. Taxanes can inhibit cancer cells dividing and reproducing. Possible associated adverse effects include nausea, vomiting and increased risk of infections. Cochrane Systematic Ferguson T. et al. Taxanes for adjuvant treatment of early breast cancer. Cochrane Reviews 2007, Issue 4. Art No: CD004421. DOI:10.1002/14651858. CD004421.pub2. This review included 12 of the 20 studies identified, involving 18,304 participants.		
taxane containing chemotherapy improves overall survival and disease-free survival in pre- or post-menopausal women with early breast cancer (cancer that has not spread beyond the breast or nearby lymph nodes and is potentially curable by surgery alone). Caveat The review did not identify a subgroup of patients where taxane containing treatment may have been more or less effective. Dosage and scheduling of the taxanes used were not clearly defined so determining the optimal use of taxanes must await the next generation of studies. Context Breast cancer is the commonest cancer in women (23% of all cancers), with an estimated 1.15 million new cases and over 411,000 deaths reported worldwide in 2002. Taxanes can inhibit cancer cells dividing and reproducing. Possible associated adverse effects include nausea, vomiting and increased risk of infections. Cochrane Systematic Review Ferguson T. et al. Taxanes for adjuvant treatment of early breast cancer. Cochrane Reviews 2007, Issue 4. Art No: CD004421. DOI:10.1002/14651858. CD004421.pub2. This review included 12 of the 20 studies identified, involving 18,304 participants.	Clinical question	. , ,
taxane containing treatment may have been more or less effective. Dosage and scheduling of the taxanes used were not clearly defined so determining the optimal use of taxanes must await the next generation of studies. Context Breast cancer is the commonest cancer in women (23% of all cancers), with an estimated 1.15 million new cases and over 411,000 deaths reported worldwide in 2002. Taxanes can inhibit cancer cells dividing and reproducing. Possible associated adverse effects include nausea, vomiting and increased risk of infections. Cochrane Systematic Review Ferguson T. et al. Taxanes for adjuvant treatment of early breast cancer. Cochrane Reviews 2007, Issue 4. Art No: CD004421. DOI:10.1002/14651858. CD004421.pub2. This review included 12 of the 20 studies identified, involving 18,304 participants.	Bottom line	taxane containing chemotherapy improves overall survival and disease-free survival in pre- or post-menopausal women with early breast cancer (cancer that has not spread beyond the breast or nearby lymph nodes
of all cancers), with an estimated 1.15 million new cases and over 411,000 deaths reported worldwide in 2002. Taxanes can inhibit cancer cells dividing and reproducing. Possible associated adverse effects include nausea, vomiting and increased risk of infections. Cochrane Systematic Review Ferguson T. et al. Taxanes for adjuvant treatment of early breast cancer. Cochrane Reviews 2007, Issue 4. Art No: CD004421. DOI:10.1002/14651858. CD004421.pub2. This review included 12 of the 20 studies identified, involving 18,304 participants.	Caveat	taxane containing treatment may have been more or less effective. Dosage and scheduling of the taxanes used were not clearly defined so determining the optimal use
Review early breast cancer. Cochrane Reviews 2007, Issue 4. Art No: CD004421. DOI:10.1002/14651858. CD004421.pub2. This review included 12 of the 20 studies identified, involving 18,304 participants.	Context	of all cancers), with an estimated 1.15 million new cases and over 411,000 deaths reported worldwide in 2002. Taxanes can inhibit cancer cells dividing and reproducing. Possible associated adverse effects include
Pearls No. 65, May 2008, written by Brian R McAvoy	_	early breast cancer. Cochrane Reviews 2007, Issue 4. Art No: CD004421. DOI:10.1002/14651858. CD004421.pub2. This review included 12 of the 20
	Pearls No. 65, May 2008,	written by Brian R McAvoy

^{*}Taxanes are an adjuvant to surgical treatment of early breast cancer, not an alternative.

PEARLS are succinct summaries of Cochrane Systematic Reviews for primary care practitioners. They are funded by the New Zealand Guidelines Group.

PEARLS provide guidance on whether a treatment is effective or ineffective. PEARLS are prepared as an educational resource and do not replace clinician judgement in the management of individual cases.